Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice

  • Rheumatoid Arthritis
Trial Status:


This trial runs in
  • Germany
Trial Identifier:

NCT02251860 ML29087

      Show trial locations

      The source of the below information is the publicly available website It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      ARATA is a prospective, non-interventional, multicenter, observational study in Germany to evaluate the long-term effectiveness and tolerability of subcutaneously administered tocilizumab in participants with rheumatoid arthritis in daily clinical practice. Participants will be followed over an observation period of up to 2 years after the initial injection.

      Hoffmann-La Roche Sponsor
      NCT02251860 , ML29087 Trial Identifier
      Rheumatoid Arthritis Condition
      Official Title

      A Prospective, Non-Interventional Study in Germany to Evaluate the Long-Term Effectiveness and Tolerability of Subcutaneously Administered RoActemra® (Tocilizumab; TCZ) in Patients With Rheumatoid Arthritis in Daily Clinical Practice (as Recommended in Label)

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants who have not yet been treated with tocilizumab
      • Participants who have received the first injection with tocilizumab maximum 1 month before inclusion in the study and the necessary baseline data and disease characteristics are present
      Exclusion Criteria
      • Participants who at the time of the study inclusion are participating in a different interventional study on rheumatoid arthritis

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now